{"analyses":[{"ciLowerLimit":"0.69","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.47","estimateComment":"Reference level = Chemoradiation arm","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.95","paramType":"Hazard Ratio (HR)","paramValue":"1.01","statisticalComment":"Two-sided significance level = 0.05","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"26.2","upperLimit":"70.4","value":"38.5"},{"groupId":"OG001","lowerLimit":"29.0","upperLimit":"64.5","value":"38.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"96"}],"units":"Participants"}],"description":"Overall survival time is defined as time from randomization to the date of death from any cause or last known follow-up (censored). Rates are estimated by the Kaplan-Meier method. Analysis occurred after 109 deaths were reported.","dispersionType":"95% Confidence Interval","groups":[{"description":"Radiation therapy with concurrent trastuzumab, paclitaxel, and carboplatin followed by surgery followed by maintenance trastuzumab","id":"OG000","title":"Chemoradiation and Trastuzumab"},{"description":"Radiation therapy with concurrent paclitaxel and carboplatin followed by surgery","id":"OG001","title":"Chemoradiation"}],"paramType":"MEDIAN","populationDescription":"Eligible randomized participants","reportingStatus":"POSTED","timeFrame":"From randomization to last follow-up. Maximum follow-up at time of analysis was 8 years.","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}